1.Reinhart   K, Daniels   R, Kissoon   N, Machado   FR, Schachter   RD, Finfer   S. Recognizing sepsis as a Global Health priority - a WHO resolution. N Engl J Med. 2017;377:414–7.

2.Lelubre   C, Vincent   JL. Mechanisms and treatment of organ failure in sepsis. Nat Rev Nephrol. 2018;14:417–27.

3.Cohen   J, Vincent   JL, Adhikari   NK, Machado   FR, Angus   DC, Calandra   T, et al.   Sepsis: a roadmap for future research. Lancet Infect Dis. 2015;15:581–614.

4.Singer   M, Deutschman   CS, Seymour   CW, Shankar-Hari   M, Annane   D, Bauer   M, et al.   The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.

5.Rajaee   A, Barnett   R, Cheadle   WG. Pathogen- and danger-associated molecular patterns and the cytokine response in sepsis. Surg Infect (Larchmt). 2018;19:107–16.

6.Delano   MJ, Ward   PA. The immune system's role in sepsis progression, resolution, and long-term outcome. Immunol Rev. 2016;274:330–53.

7.Hotchkiss   RS, Monneret   G, Payen   D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13:862–74.

8.van  Vught   LA, Klein Klouwenberg   PM, Spitoni   C, Scicluna   BP, Wiewel   MA, Horn   J, et al.   Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA. 2016;315:1469–79.

9.Kamada   N, Seo   SU, Chen   GY, Núñez   G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 2013;13:321–35.

10.Rodríguez   C, Romero   E, Garrido-Sanchez   L, Alcaín-Martínez   G, Andrade   RJ, Taminiau   B, et al.   Microbiota insights in clostridium difficile infection and inflammatory bowel disease. Gut Microbes. 2020;12:1725220.

11.Tilg   H, Cani   PD, Mayer   EA. Gut microbiome and liver diseases. Gut. 2016;65:2035–44.

12.Haak   BW, Wiersinga   WJ. The role of the gut microbiota in sepsis. Lancet Gastroenterol Hepatol. 2017;2:135–43.

13.Liu   Z, Li   N, Fang   H, Chen   X, Guo   Y, Gong   S, et al.   Enteric dysbiosis is associated with sepsis in patients. FASEB J. 2019;33:12299–310.

14.Graspeuntner   S, Waschina   S, Künzel   S, Twisselmann   N, Rausch   TK, Cloppenborg-Schmidt   K, et al.   Gut Dysbiosis with bacilli dominance and accumulation of fermentation products precedes late-onset sepsis in preterm infants. Clin Infect Dis. 2019;69:268–77.

15.Hayakawa   M, Asahara   T, Henzan   N, Murakami   H, Yamamoto   H, Mukai   N, et al.   Dramatic changes of the gut flora immediately after severe and sudden insults. Dig Dis Sci. 2011;56:2361–5.

16.Ravi   A, Halstead   FD, Bamford   A, Casey   A, Thomson   NM, van  Schaik   W, et al.   Loss of microbial diversity and pathogen domination of the gut microbiota in critically ill patients. Microb Genom. 2019;5.

17.Shimizu   K, Ogura   H, Goto   M, Asahara   T, Nomoto   K, Morotomi   M, et al.   Altered gut flora and environment in patients with severe SIRS. J Trauma. 2006;60:126–33.

18.Shimizu   K, Ogura   H, Hamasaki   T, Goto   M, Tasaki   O, Asahara   T, et al.   Altered gut flora are associated with septic complications and death in critically ill patients with systemic inflammatory response syndrome. Dig Dis Sci. 2011;56:1171–7.

19.Guarner   F, Malagelada   JR. Gut flora in health and disease. Lancet. 2003;361:512–9.

20.Yamada   T, Shimizu   K, Ogura   H, Asahara   T, Nomoto   K, Yamakawa   K, et al.   Rapid and sustained Long-term decrease of Fecal short-chain fatty acids in critically ill patients with systemic inflammatory response syndrome. JPEN J Parenter Enteral Nutr. 2015;39:569–77.

21.Martin-Gallausiaux   C, Marinelli   L, Blottière   HM, Larraufie   P, Lapaque   N. SCFA: mechanisms and functional importance in the gut. Proc Nutr Soc. 2021;80:37–49.

22.Clarke   TB. Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via nod-like receptor ligands. Infect Immun. 2014;82:4596–606.

23.Clarke   TB, Davis   KM, Lysenko   ES, Zhou   AY, Yu   Y, Weiser   JN. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat Med. 2010;16:228–31.

24.Dickson   RP. The microbiome and critical illness. Lancet Respir Med. 2016;4:59–72.

25.Zhang   D, Chen   G, Manwani   D, Mortha   A, Xu   C, Faith   JJ, et al.   Neutrophil ageing is regulated by the microbiome. Nature. 2015;525:528–32.

26.Schuijt   TJ, Lankelma   JM, Scicluna   BP, de Sousa e Melo   F, Roelofs   JJ, de  Boer   JD. Et al., The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut. 2016;65:575–83.

27.Oteo   J, Pérez-Vázquez   M, Campos   J. Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010;23:320–6.

28.Ayres   JS, Trinidad   NJ, Vance   RE. Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota. Nat Med. 2012;18:799–806.

29.Rakoff-Nahoum   S, Paglino   J, Eslami-Varzaneh   F, Edberg   S, Medzhitov   R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118:229–41.

30.Mukherji   A, Kobiita   A, Ye   T, Chambon   P. Homeostasis in intestinal epithelium is orchestrated by the circadian clock and microbiota cues transduced by TLRs. Cell. 2013;153:812–27.

31.Zeng   MY, Cisalpino   D, Varadarajan   S, Hellman   J, Warren   HS, Cascalho   M, et al.   Gut microbiota-induced immunoglobulin G controls systemic infection by symbiotic bacteria and pathogens. Immunity. 2016;44:647–58.

32.Belkaid   Y, Hand   TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157:121–41.

33.Sonnenburg   JL, Bäckhed   F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016;535:56–64.

34.Morowitz   MJ, Di Caro   V, Pang   D, Cummings   J, Firek   B, Rogers   MB, et al.   Dietary supplementation with nonfermentable Fiber alters the gut microbiota and confers protection in murine models of sepsis. Crit Care Med. 2017;45:e516–23.

35.Wu   T, Li   H, Su   C, Xu   F, Yang   G, Sun   K, et al.   Microbiota-derived short-chain fatty acids promote LAMTOR2-mediated immune responses in macrophages. mSystems. 2020;5.

36.Gong   S, Yan   Z, Liu   Z, Niu   M, Fang   H, Li   N, et al.   Intestinal microbiota mediates the susceptibility to Polymicrobial sepsis-induced liver injury by Granisetron generation in mice. Hepatology. 2019;69:1751–67.

37.Fay   KT, Klingensmith   NJ, Chen   CW, Zhang   W, Sun   Y, Morrow   KN, et al.   The gut microbiome alters immunophenotype and survival from sepsis. FASEB J. 2019;33:11258–69.

38.Wilmore   JR, Gaudette   BT, Gomez Atria   D, Hashemi   T, Jones   DD, Gardner   CA, et al.   Commensal microbes induce serum IgA responses that protect against Polymicrobial sepsis. Cell Host Microbe. 2018;23:302–311.e3.

39.Moor   K, Diard   M, Sellin   ME, Felmy   B, Wotzka   SY, Toska   A, et al.   High-avidity IgA protects the intestine by enchaining growing bacteria. Nature. 2017;544:498–502.

40.Peterson   LW, Artis   D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol. 2014;14:141–53.

41.Zeisel   MB, Dhawan   P, Baumert   TF. Tight junction proteins in gastrointestinal and liver disease. Gut. 2019;68:547–61.

42.Fink   MP. Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness. Curr Opin Crit Care. 2003;9:143–51.

43.He   W, Wang   Y, Wang   P, Wang   F. Intestinal barrier dysfunction in severe burn injury. Burns Trauma. 2019;7:24.

44.Feng   Y, Huang   Y, Wang   Y, Wang   P, Wang   F. Severe burn injury alters intestinal microbiota composition and impairs intestinal barrier in mice. Burns Trauma. 2019;7:20.

45.Kuethe   JW, Armocida   SM, Midura   EF, Rice   TC, Hildeman   DA, Healy   DP, et al.   Fecal microbiota transplant restores mucosal integrity in a murine model of burn injury. Shock. 2016;45:647–52.

46.Li   Q, Zhang   Q, Wang   C, Liu   X, Li   N, Li   J. Disruption of tight junctions during polymicrobial sepsis in vivo. J Pathol. 2009;218:210–21.

47.Yoseph   BP, Klingensmith   NJ, Liang   Z, Breed   ER, Burd   EM, Mittal   R, et al.   Mechanisms of intestinal barrier dysfunction in sepsis. Shock. 2016;46:52–9.

48.Fay   KT, Ford   ML, Coopersmith   CM. The intestinal microenvironment in sepsis. Biochim Biophys Acta Mol Basis Dis. 2017;1863:2574–83.

49.Haussner   F, Chakraborty   S, Halbgebauer   R, Huber-Lang   M. Challenge to the intestinal mucosa during sepsis. Front Immunol. 2019;10:891.

50.Fischer   A, Gluth   M, Pape   UF, Wiedenmann   B, Theuring   F, Baumgart   DC. Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2013;304:G970–9.

51.Yang   R, Han   X, Uchiyama   T, Watkins   SK, Yaguchi   A, Delude   RL, et al.   IL-6 is essential for development of gut barrier dysfunction after hemorrhagic shock and resuscitation in mice. Am J Physiol Gastrointest Liver Physiol. 2003;285:G621–9.

52.Al-Sadi   RM, Ma   TY. IL-1beta causes an increase in intestinal epithelial tight junction permeability. J Immunol. 2007;178:4641–9.

53.Turner   JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9:799–809.

54.Lorentz   CA, Liang   Z, Meng   M, Chen   CW, Yoseph   BP, Breed   ER, et al.   Myosin light chain kinase knockout improves gut barrier function and confers a survival advantage in polymicrobial sepsis. Mol Med. 2017;23:155–65.

55.Hotchkiss   RS, Swanson   PE, Freeman   BD, Tinsley   KW, Cobb   JP, Matuschak   GM, et al.   Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med. 1999;27:1230–51.

56.Chen   WY, Wang   M, Zhang   J, Barve   SS, McClain   CJ, Joshi-Barve   S. Acrolein disrupts tight junction proteins and causes endoplasmic reticulum stress-mediated epithelial cell death leading to intestinal barrier dysfunction and permeability. Am J Pathol. 2017;187:2686–97.

57.Otani   S, Oami   T, Yoseph   BP, Klingensmith   NJ, Chen   CW, Liang   Z, et al.   Overexpression of BCL-2 in the intestinal epithelium prevents sepsis-induced gut barrier dysfunction via altering tight junction protein expression. Shock. 2020;54:330–6.

58.Clark   JA, Clark   AT, Hotchkiss   RS, Buchman   TG, Coopersmith   CM. Epidermal growth factor treatment decreases mortality and is associated with improved gut integrity in sepsis. Shock. 2008;30:36–42.

59.Clark   JA, Gan   H, Samocha   AJ, Fox   AC, Buchman   TG, Coopersmith   CM. Enterocyte-specific epidermal growth factor prevents barrier dysfunction and improves mortality in murine peritonitis. Am J Physiol Gastrointest Liver Physiol. 2009;297:G471–9.

60.Hu   J, Luo   H, Wang   J, Tang   W, Lu   J, Wu   S, et al.   Enteric dysbiosis-linked gut barrier disruption triggers early renal injury induced by chronic high salt feeding in mice. Exp Mol Med. 2017;49:e370.

61.Assimakopoulos   SF, Papadopoulou   I, Bantouna   D, de  Lastic   AL, Rodi   M, Mouzaki   A, et al.   Fecal microbiota transplantation and hydrocortisone ameliorate intestinal barrier dysfunction and improve survival in a rat model of Cecal ligation and puncture-induced sepsis. Shock. 2020;55:666–75.

62.Vaishnavi   C. Translocation of gut flora and its role in sepsis. Indian J Med Microbiol. 2013;31:334–42.

63.Park   KS, Lee   J, Lee   C, Park   HT, Kim   JW, Kim   OY, et al.   Sepsis-like systemic inflammation induced by Nano-sized extracellular vesicles from Feces. Front Microbiol. 2018;9:1735.

64.O'Boyle   CJ, MacFie   J, Mitchell   CJ, Johnstone   D, Sagar   PM, Sedman   PC. Microbiology of bacterial translocation in humans. Gut. 1998;42:29–35.

65.Edwin   A, DEITCH   DA, Zhong   XU, Qi   LU. Gut lymph hypothesis of early shock and trauma-induced multiple organ dysfunction syndrome: a new look at gut origin sepsis. Journal of Organ Dysfunction. 2006;2:70–9.

66.Berg   RD, Garlington   AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun. 1979;23:403–11.

67.Badami   CD, Senthil   M, Caputo   FJ, Rupani   BJ, Doucet   D, Pisarenko   V, et al.   Mesenteric lymph duct ligation improves survival in a lethal shock model. Shock. 2008;30:680–5.

68.Senthil   M, Watkins   A, Barlos   D, Xu   DZ, Lu   Q, Abungu   B, et al.   Intravenous injection of trauma-hemorrhagic shock mesenteric lymph causes lung injury that is dependent upon activation of the inducible nitric oxide synthase pathway. Ann Surg. 2007;246:822–30.

69.Sun   J, Zhang   J, Wang   X, Ji   F, Ronco   C, Tian   J, et al.   Gut-liver crosstalk in sepsis-induced liver injury. Crit Care. 2020;24:614.

70.Protzer   U, Maini   MK, Knolle   PA. Living in the liver: hepatic infections. Nat Rev Immunol. 2012;12:201–13.

71.Wahlström   A, Sayin   SI, Marschall   HU, Bäckhed   F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24:41–50.

72.Fiorucci   S, Biagioli   M, Zampella   A, Distrutti   E. Bile acids activated receptors regulate innate immunity. Front Immunol. 2018;9:1853.

73.Broadley   SP, Plaumann   A, Coletti   R, Lehmann   C, Wanisch   A, Seidlmeier   A, et al.   Dual-track clearance of circulating bacteria balances rapid restoration of blood sterility with induction of adaptive immunity. Cell Host Microbe. 2016;20:36–48.

74.Luo   Z, Ji   Y, Gao   H, Gomes Dos Reis   FC, Bandyopadhyay   G, Jin   Z. Et al, CRIg(+) macrophages prevent gut microbial DNA-containing extracellular vesicle-induced tissue inflammation and insulin resistance. Gastroenterology. 2021;160:863–74.

75.Zeng   Z, Surewaard   BG, Wong   CH, Geoghegan   JA, Jenne   CN, Kubes   P. CRIg functions as a macrophage pattern recognition receptor to directly bind and capture blood-borne gram-positive bacteria. Cell Host Microbe. 2016;20:99–106.

76.McDonald   B, Zucoloto   AZ, Yu   IL, Burkhard   R, Brown   K, Geuking   MB, et al.   Programing of an intravascular immune firewall by the gut microbiota protects against pathogen dissemination during infection. Cell Host Microbe. 2020;28:660–668.e4.

77.Blériot   C, Dupuis   T, Jouvion   G, Eberl   G, Disson   O, Lecuit   M. Liver-resident macrophage necroptosis orchestrates type 1 microbicidal inflammation and type-2-mediated tissue repair during bacterial infection. Immunity. 2015;42:145–58.

78.Wan   J, Benkdane   M, Teixeira-Clerc   F, Bonnafous   S, Louvet   A, Lafdil   F, et al.   M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. Hepatology. 2014;59:130–42.

79.Strnad   P, Tacke   F, Koch   A, Trautwein   C. Liver - guardian, modifier and target of sepsis. Nat Rev Gastroenterol Hepatol. 2017;14:55–66.

80.Jan   AT. Outer membrane vesicles (OMVs) of gram-negative bacteria: a perspective update. Front Microbiol. 2017;8:1053.

81.Kaparakis-Liaskos   M, Ferrero   RL. Immune modulation by bacterial outer membrane vesicles. Nat Rev Immunol. 2015;15:375–87.

82.Shah   B, Sullivan   CJ, Lonergan   NE, Stanley   S, Soult   MC, Britt   LD. Circulating bacterial membrane vesicles cause sepsis in rats. Shock. 2012;37:621–8.

83.Vanaja   SK, Russo   AJ, Behl   B, Banerjee   I, Yankova   M, Deshmukh   SD, et al.   Bacterial outer membrane vesicles mediate cytosolic localization of LPS and Caspase-11 activation. Cell. 2016;165:1106–19.

84.Huang   W, Yao   Y, Long   Q, Yang   X, Sun   W, Liu   C, et al.   Immunization against multidrug-resistant Acinetobacter baumannii effectively protects mice in both pneumonia and sepsis models. PLoS One. 2014;9:e100727.

85.Nieves   W, Petersen   H, Judy   BM, Blumentritt   CA, Russell-Lodrigue   K, Roy   CJ, et al.   A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis. Clin Vaccine Immunol. 2014;21:747–54.

86.Kim   OY, Hong   BS, Park   KS, Yoon   YJ, Choi   SJ, Lee   WH, et al.   Immunization with Escherichia coli outer membrane vesicles protects bacteria-induced lethality via Th1 and Th17 cell responses. J Immunol. 2013;190:4092–102.

87.Mortaş   H, Bilici   S, Karakan   T. The circadian disruption of night work alters gut microbiota consistent with elevated risk for future metabolic and gastrointestinal pathology. Chronobiol Int. 2020;37:1067–81.

88.Thaiss   CA, Zeevi   D, Levy   M, Zilberman-Schapira   G, Suez   J, Tengeler   AC, et al.   Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell. 2014;159:514–29.

89.Bellet   MM, Deriu   E, Liu   JZ, Grimaldi   B, Blaschitz   C, Zeller   M, et al.   Circadian clock regulates the host response to salmonella. Proc Natl Acad Sci U S A. 2013;110:9897–902.

90.Rosselot   AE, Hong   CI, Moore   SR. Rhythm and bugs: circadian clocks, gut microbiota, and enteric infections. Curr Opin Gastroenterol. 2016;32:7–11.

91.Wu   G, Tang   W, He   Y, Hu   J, Gong   S, He   Z, et al.   Light exposure influences the diurnal oscillation of gut microbiota in mice. Biochem Biophys Res Commun. 2018;501:16–23.

92.Parkar   SG, Kalsbeek   A, Cheeseman   JF. Potential role for the gut microbiota in modulating host circadian rhythms and metabolic health. Microorganisms. 2019;7:41.

93.Tognini   P, Thaiss   CA, Elinav   E, Sassone-Corsi   P. Circadian coordination of antimicrobial responses. Cell Host Microbe. 2017;22:185–92.

94.Yu   X, Rollins   D, Ruhn   KA, Stubblefield   JJ, Green   CB, Kashiwada   M, et al.   TH17 cell differentiation is regulated by the circadian clock. Science. 2013;342:727–30.

95.Ojima   M, Motooka   D, Shimizu   K, Gotoh   K, Shintani   A, Yoshiya   K, et al.   Metagenomic analysis reveals dynamic changes of whole gut microbiota in the acute phase of intensive care unit patients. Dig Dis Sci. 2016;61:1628–34.

96.Carlson   DE, Chiu   WC. The absence of circadian cues during recovery from sepsis modifies pituitary-adrenocortical function and impairs survival. Shock. 2008;29:127–32.

97.Zhang   Y, Xie   B, Chen   X, Zhang   J, Yuan   S. A key role of gut microbiota-vagus nerve/spleen axis in sleep deprivation-mediated aggravation of systemic inflammation after LPS administration. Life Sci. 2021;265:118736.

98.Deaver   JA, Eum   SY, Toborek   M. Circadian disruption changes gut microbiome taxa and functional gene composition. Front Microbiol. 2018;9:737.

99.Cui   M, Xiao   H, Luo   D, Zhang   X, Zhao   S, Zheng   Q, et al.   Circadian rhythm shapes the gut microbiota affecting host Radiosensitivity. Int J Mol Sci. 2016;17:1786.

100.Christoffersson   G, Vågesjö   E, Pettersson   US, Massena   S, Nilsson   EK, Broman   JE, et al.   Acute sleep deprivation in healthy young men: impact on population diversity and function of circulating neutrophils. Brain Behav Immun. 2014;41:162–72.

101.Keskey   R, Cone   JT, DeFazio   JR, Alverdy   JC. The use of fecal microbiota transplant in sepsis. Transl Res. 2020;226:12–25.

102.Haifer   C, Leong   RW, Paramsothy   S. The role of faecal microbiota transplantation in the treatment of inflammatory bowel disease. Curr Opin Pharmacol. 2020;55:8–16.

103.Chen   D, Wu   J, Jin   D, Wang   B, Cao   H. Fecal microbiota transplantation in cancer management: current status and perspectives. Int J Cancer. 2019;145:2021–31.

104.Weingarden   AR, Chen   C, Bobr   A, Yao   D, Lu   Y, Nelson   VM, et al.   Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol. 2014;306:G310–9.

105.van  Nood   E, Vrieze   A, Nieuwdorp   M, Fuentes   S, Zoetendal   EG, de  Vos   WM, et al.   Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–15.

106.Li   Q, Wang   C, Tang   C, He   Q, Zhao   X, Li   N, et al.   Successful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation: a case report. Crit Care. 2015;19:37.

107.Wei   Y, Yang   J, Wang   J, Yang   Y, Huang   J, Gong   H, et al.   Successful treatment with fecal microbiota transplantation in patients with multiple organ dysfunction syndrome and diarrhea following severe sepsis. Crit Care. 2016;20:332.

108.Kim   SM, DeFazio   JR, Hyoju   SK, Sangani   K, Keskey   R, Krezalek   MA, et al.   Fecal microbiota transplant rescues mice from human pathogen mediated sepsis by restoring systemic immunity. Nat Commun. 2020;11:2354.

109.Li   S, Lv   J, Li   J, Zhao   Z, Guo   H, Zhang   Y, et al.   Intestinal microbiota impact sepsis associated encephalopathy via the vagus nerve. Neurosci Lett. 2018;662:98–104.

110.Suez   J, Zmora   N, Segal   E, Elinav   E. The pros, cons, and many unknowns of probiotics. Nat Med. 2019;25:716–29.

111.Wang   H, Gong   J, Wang   W, Long   Y, Fu   X, Fu   Y, et al.   Are there any different effects of Bifidobacterium, lactobacillus and streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model?  PLoS One. 2014;9:e90153.

112.Markowiak   P, Śliżewska   K. Effects of probiotics, prebiotics, and Synbiotics on human health. Nutrients. 2017;9:1021.

113.Vulevic   J, Juric   A, Walton   GE, Claus   SP, Tzortzis   G, Toward   RE, et al.   Influence of galacto-oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabonomics in elderly persons. Br J Nutr. 2015;114:586–95.

114.Panigrahi   P, Parida   S, Nanda   NC, Satpathy   R, Pradhan   L, Chandel   DS, et al.   A randomized synbiotic trial to prevent sepsis among infants in rural India. Nature. 2017;548:407–12.

115.Shimizu   K, Yamada   T, Ogura   H, Mohri   T, Kiguchi   T, Fujimi   S, et al.   Synbiotics modulate gut microbiota and reduce enteritis and ventilator-associated pneumonia in patients with sepsis: a randomized controlled trial. Crit Care. 2018;22:239.

116.Kanic   Z, Micetic Turk   D, Burja   S, Kanic   V, Dinevski   D. Influence of a combination of probiotics on bacterial infections in very low birthweight newborns. Wien Klin Wochenschr. 2015;127:S210–5.

117.Cui   X, Shi   Y, Gao   S, Xue   X, Fu   J. Effects of lactobacillus reuteri DSM 17938 in preterm infants: a double-blinded randomized controlled study. Ital J Pediatr. 2019;45:140.

118.Stadlbauer   V, Horvath   A, Komarova   I, Schmerboeck   B, Feldbacher   N, Klymiuk   I, et al.   Dysbiosis in early sepsis can be modulated by a multispecies probiotic: a randomised controlled pilot trial. Benef Microbes. 2019;10:265–78.

119.Thomas   CM, Versalovic   J. Probiotics-host communication: modulation of signaling pathways in the intestine. Gut Microbes. 2010;1:148–63.

120.Rao   SC, Athalye-Jape   GK, Deshpande   GC, Simmer   KN, Patole   SK. Probiotic supplementation and late-onset sepsis in preterm infants: a meta-analysis. Pediatrics. 2016;137:e20153684.

121.Chen   L, Xu   K, Gui   Q, Chen   Y, Chen   D, Yang   Y. Probiotic pre-administration reduces mortality in a mouse model of cecal ligation and puncture-induced sepsis. Exp Ther Med. 2016;12:1836–42.

122.Chen   L, Li   H, Chen   Y, Yang   Y. Probiotic lactobacillus rhamnosus GG reduces mortality of septic mice by modulating gut microbiota composition and metabolic profiles. Nutrition. 2020;78:110863.

123.Singer   JR, Blosser   EG, Zindl   CL, Silberger   DJ, Conlan   S, Laufer   VA, et al.   Preventing dysbiosis of the neonatal mouse intestinal microbiome protects against late-onset sepsis. Nat Med. 2019;25:1772–82.

124.Chen   L, Li   H, Li   J, Chen   Y, Yang   Y. Lactobacillus rhamnosus GG treatment improves intestinal permeability and modulates microbiota dysbiosis in an experimental model of sepsis. Int J Mol Med. 2019;43:1139–48.

125.Zhou   JS, Shu   Q, Rutherfurd   KJ, Prasad   J, Birtles   MJ, Gopal   PK, et al.   Safety assessment of potential probiotic lactic acid bacterial strains lactobacillus rhamnosus HN001, lb. acidophilus HN017, and Bifidobacterium lactis HN019 in BALB/c mice. Int J Food Microbiol. 2000;56:87–96.

126.Yelin   I, Flett   KB, Merakou   C, Mehrotra   P, Stam   J, Snesrud   E, et al.   Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nat Med. 2019;25:1728–32.

127.Cannon   JP, Lee   TA, Bolanos   JT, Danziger   LH. Pathogenic relevance of lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis. 2005;24:31–40.

128.McNaught   CE, Woodcock   NP, MacFie   J, Mitchell   CJ. A prospective randomised study of the probiotic lactobacillus plantarum 299V on indices of gut barrier function in elective surgical patients. Gut. 2002;51:827–31.

129.Barraud   D, Blard   C, Hein   F, Marçon   O, Cravoisy   A, Nace   L, et al.   Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial. Intensive Care Med. 2010;36:1540–7.

130.Besselink   MG, van  Santvoort   HC, Renooij   W, de  Smet   MB, Boermeester   MA, Fischer   K, et al.   Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis. Ann Surg. 2009;250:712–9.

131.Górski   A, Dąbrowska   K, Międzybrodzki   R, Weber-Dąbrowska   B, Łusiak-Szelachowska   M, Jończyk-Matysiak   E, et al.   Phages and immunomodulation. Future Microbiol. 2017;12:905–14.

132.Van Belleghem   JD, Clement   F, Merabishvili   M, Lavigne   R, Vaneechoutte   M. Pro- and anti-inflammatory responses of peripheral blood mononuclear cells induced by Staphylococcus aureus and Pseudomonas aeruginosa phages. Sci Rep. 2017;7:8004.

133.Pirisi   A. Phage therapy--advantages over antibiotics?  Lancet. 2000;356:1418.

134.Kutateladze   M, Adamia   R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010;28:591–5.

135.Wu   M, Hu   K, Xie   Y, Liu   Y, Mu   D, Guo   H, et al.   A novel phage PD-6A3, and its Endolysin Ply6A3, with extended lytic activity against Acinetobacter baumannii. Front Microbiol. 2018;9:3302.

136.Gorski   A, Jonczyk-Matysiak   E, Lusiak-Szelachowska   M, Miedzybrodzki   R, Weber-Dabrowska   B, Borysowski   J. The potential of phage therapy in sepsis. Front Immunol. 2017;8:1783.

137.Gatea Kaabi   SA, Musafer   HK. New phage cocktail against infantile sepsis bacteria. Microb Pathog. 2020;148:104447.

138.Petrovic Fabijan   A, Lin   RCY, Ho   J, Maddocks   S, Ben Zakour   NL, Iredell   JR, et al.   Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nat Microbiol. 2020;5:465–72.

139.Hsu   BB, Gibson   TE, Yeliseyev   V, Liu   Q, Lyon   L, Bry   L, et al.   Dynamic modulation of the gut microbiota and metabolome by bacteriophages in a mouse model. Cell Host Microbe. 2019;25:803–814.e5.